PL2590645T3 - Związki karbaminianowe do leczenia zaburzenia dwubiegunowego - Google Patents

Związki karbaminianowe do leczenia zaburzenia dwubiegunowego

Info

Publication number
PL2590645T3
PL2590645T3 PL11801093T PL11801093T PL2590645T3 PL 2590645 T3 PL2590645 T3 PL 2590645T3 PL 11801093 T PL11801093 T PL 11801093T PL 11801093 T PL11801093 T PL 11801093T PL 2590645 T3 PL2590645 T3 PL 2590645T3
Authority
PL
Poland
Prior art keywords
bipolar disorder
carbamate compounds
treating bipolar
treating
carbamate
Prior art date
Application number
PL11801093T
Other languages
English (en)
Polish (pl)
Inventor
Sung James Lee
Susan Marie Melnick
Original Assignee
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co., Ltd. filed Critical Sk Biopharmaceuticals Co., Ltd.
Publication of PL2590645T3 publication Critical patent/PL2590645T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11801093T 2010-06-30 2011-06-27 Związki karbaminianowe do leczenia zaburzenia dwubiegunowego PL2590645T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/827,505 US9610274B2 (en) 2010-06-30 2010-06-30 Methods for treating bipolar disorder
PCT/KR2011/004676 WO2012002687A2 (en) 2010-06-30 2011-06-27 Methods for treating bipolar disorder
EP11801093.3A EP2590645B1 (en) 2010-06-30 2011-06-27 Carbamate compounds for treating bipolar disorder

Publications (1)

Publication Number Publication Date
PL2590645T3 true PL2590645T3 (pl) 2018-03-30

Family

ID=45400168

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11801093T PL2590645T3 (pl) 2010-06-30 2011-06-27 Związki karbaminianowe do leczenia zaburzenia dwubiegunowego

Country Status (13)

Country Link
US (2) US9610274B2 (cg-RX-API-DMAC7.html)
EP (1) EP2590645B1 (cg-RX-API-DMAC7.html)
JP (1) JP5881692B2 (cg-RX-API-DMAC7.html)
KR (1) KR101828934B1 (cg-RX-API-DMAC7.html)
CN (1) CN102985085B (cg-RX-API-DMAC7.html)
AU (1) AU2011272156B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012033738A2 (cg-RX-API-DMAC7.html)
CA (1) CA2801241C (cg-RX-API-DMAC7.html)
ES (1) ES2654615T3 (cg-RX-API-DMAC7.html)
MX (2) MX360030B (cg-RX-API-DMAC7.html)
PL (1) PL2590645T3 (cg-RX-API-DMAC7.html)
RU (1) RU2653408C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012002687A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101335941B1 (ko) 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
MX2012000034A (es) 2009-06-22 2012-02-21 Sk Biopharmaceuticals Co Ltd Metodos para el tratamiento o la prevencion de la fatiga.
RU2019114940A (ru) 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
US9226910B2 (en) 2013-07-18 2016-01-05 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
CA3036071A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
US10710958B2 (en) 2016-10-06 2020-07-14 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol compounds and uses thereof
KR102635938B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
RU2020108634A (ru) 2017-07-31 2021-09-02 Джаз Фармасьютикалз Айрлэнд Лимитед Аналоги карбамоилфенилаланинола и способы их применения
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109872A (en) 1993-06-10 2000-12-06 Lilly Co Eli Tetrahydrobenz ¬CD¾ indole-6-carboxamides for use in preventing emesis and pharmaceutical compositions comprising same
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DE69618663T2 (de) 1996-10-10 2002-08-14 Sk Corp., Seoul/Soul O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
RU2214400C2 (ru) 1998-04-28 2003-10-20 Дайниппон Фармасьютикал Ко., Лтд. Производные 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
PT1347971E (pt) 2000-12-21 2006-06-30 Bristol Myers Squibb Co Inibidores tiazolilicos de tirosina-cinases da familia tec
WO2002067922A1 (en) 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
KR100858232B1 (ko) 2001-02-27 2008-09-12 오르토-맥네일 파마슈티칼, 인코퍼레이티드 카바메이트 화합물을 포함하는 거동 장애 예방 또는 치료용 약제학적 조성물
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
CA2449249A1 (en) 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
BR0314584A (pt) 2002-09-20 2005-08-09 Pfizer Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4
CA2523077A1 (en) 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
HRP20120077T1 (hr) 2003-09-03 2012-02-29 Pfizer Inc. Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
KR20070083826A (ko) 2004-10-28 2007-08-24 에스케이 주식회사 우울증을 위한 부가 요법
EP1869019B1 (en) 2005-04-08 2014-08-27 Pfizer Products Inc. Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
KR101335941B1 (ko) 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
JP5298334B2 (ja) 2005-06-22 2013-09-25 エスケー ホルディングス カンパニー リミテッド 性機能障害を治療する方法
EP1928451B1 (en) 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
BRPI0719275A2 (pt) 2006-10-13 2014-04-29 Janssen Pharmaceutica Nv Composições de carbamatos de fenil-alquil-amino
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
MX2012000034A (es) 2009-06-22 2012-02-21 Sk Biopharmaceuticals Co Ltd Metodos para el tratamiento o la prevencion de la fatiga.
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101097605B1 (ko) 2009-11-04 2011-12-22 알.에프 에이치아이씨 주식회사 도허티 증폭기
AU2010316172B2 (en) 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Also Published As

Publication number Publication date
KR101828934B1 (ko) 2018-03-29
CN102985085A (zh) 2013-03-20
JP5881692B2 (ja) 2016-03-09
EP2590645A2 (en) 2013-05-15
WO2012002687A3 (en) 2012-04-26
AU2011272156A1 (en) 2013-02-07
US20170151209A1 (en) 2017-06-01
BR112012033738A2 (pt) 2017-08-08
EP2590645B1 (en) 2017-10-04
CA2801241A1 (en) 2012-01-05
MX2012014686A (es) 2013-02-11
CN102985085B (zh) 2018-10-02
AU2011272156B2 (en) 2015-02-12
US20120004300A1 (en) 2012-01-05
US9907777B2 (en) 2018-03-06
KR20130112706A (ko) 2013-10-14
WO2012002687A2 (en) 2012-01-05
RU2012155118A (ru) 2014-08-10
EP2590645A4 (en) 2014-01-22
MX360030B (es) 2018-10-19
RU2653408C2 (ru) 2018-05-08
CA2801241C (en) 2018-07-17
ES2654615T3 (es) 2018-02-14
JP2013533253A (ja) 2013-08-22
US9610274B2 (en) 2017-04-04

Similar Documents

Publication Publication Date Title
PL2590645T3 (pl) Związki karbaminianowe do leczenia zaburzenia dwubiegunowego
LT2635282T (lt) Mielofibrozės gydymui skirtos kompozicijos
IL253421B (en) Compounds for the treatment of fibrosis (Leifat)
IL225623A0 (en) Psoriasis treatment methods
ZA201402057B (en) Cachexia treatment
GB201010359D0 (en) Compounds for treating proliferative disorders
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
ZA201209270B (en) Mixture for treating fertilizers
ZA201308117B (en) Avian-based treatment
SI2590966T1 (sl) Kinazolinske spojine
GB201120594D0 (en) Catalyst compounds
GB201102283D0 (en) Treatment
GB201116328D0 (en) Treatment for tumours
IL213610A0 (en) Composition for treating dermatological conditions
GB201009495D0 (en) Compounds for treating proliferative disorders
GB201019034D0 (en) Treatment for tumors
GB201000771D0 (en) Compound for therapy
GB201118482D0 (en) Treating tumours
EP2740724A4 (en) COMPOUND FOR TREATING CARTILAGE DISORDERS
GB201015971D0 (en) Cure for epilepsy
GB201102269D0 (en) Treatment
GB201102288D0 (en) Treatment
GB201102284D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102268D0 (en) Treatment